它允许通过仿制药竞争以降低价格。
难怪仿制药公司越来越有信心。
“仿制药公司需要更加灵活精干和积极进取”，他说。
"Generics firms need to be nimble and aggressive," he observes.
第二，仿制药生产商不断合并，每种药物的生产商通常只有一两个公司。
Second, generic drugmakers have merged, so a given drug is often made by just one or two companies.
但拥有专利的罗氏药物公司不希望穷国为本国生产廉价仿制药。
But Roche — the drug company that owns the patent — doesn't want the poor world making cheaper copies for themselves.
综上所述，以上趋势表明，2010年将是全球仿制药产业的转折点。
Taken together, these trends point to 2010 being a turning-point for the global generics business.
尽管中国具有增长潜力，但主要生产仿制药的国内企业，仍占据约四分之三的市场。
In spite of China's growth potential, local companies, which mainly produce generic drugs, still account for about three quarters of the market.
一旦某种药物失去专利保护，仿制药生产商就会一拥而上争夺市场份额，导致价格暴跌。
After a drug loses its patent protection, its price plunges as generic drugmakers fight for market share.
报告指出，在许多国家，如果采用鼓励使用仿制药政策，可以节省大约60%的药费。
As the report notes, a policy that encourages the use of generic medicines could save around 60% of the costs of medicines in many countries.
但他也表示，这次他非常谨慎地看待新仿制药物的前景，因为生物技术药物很难仿制。
But he also said he was more cautious about the promise of generics this time, because biotech medicines were not easy to copy.
仅一个月前，葛兰素史克获得南非仿制药制造商阿斯彭(aspen) 16%的股份。
Only the month before GSK had acquired 16% of Aspen, a South African maker of generics.
在这些领域，许多厂商除生产供国内使用的医疗产品外，还大量出口，特别是出口仿制药。
And many have a high volume of exports in these sectors, especially for generic medicines, in addition to producing medical products for domestic use.
世卫组织推动使用仿制药品，反对为符合世卫组织标准的仿制产品的生产和国际贸易设置障碍。
WHO promotes generic medicines and opposes barriers to the production and international trade of generic products that meet WHO standards.
像立普妥这样的拳头产品的专利过期时，来自仿制药的竞争使其价格暴跌，有时不足原价的十分之一。
When patents on blockbusters like Lipitor run out, generic competition ensures that prices collapse quickly-sometimes to a tenth of their former levels.
另有一些公司走得远一些，如英国的葛兰素史克最近收购了一家非洲品牌仿制药公司阿斯彭aspen的股份。
Others have gone a bit further, as Britain's GlaxoSmithKline did with its recent acquisition of a share in Aspen, an African firm specialising in branded generics.
另有一些公司走得远一些，如英国的葛兰素史克最近收购了一家非洲品牌仿制药公司阿斯彭aspen的股份。
Others have gone a bit further, as Britain's GlaxoSmithKline did with its recent acquisition of a share in Aspen, an African firm specialising in branded generics.
应用推荐